apalutamide: Clinical Trials

24 trials of apalutamide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 active not recruiting, 9 recruiting, 2 terminated, 1 completed. 24 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 324Active not recruiting 11, Recruiting 9, Terminated 2, Completed 1, Withdrawn 1
Phase 21Active not recruiting 1

Follow apalutamide: new trials by email Literature Review of apalutamide trials Research Report on apalutamide

Trials (filtered) newest first · largest first

All 24 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
Abiraterone, Apalutamide, Enzalutamide or Darolutamide (ARPI therapy) (per standard of care) therapy - Prostate Cancer, mHSPC
Phase 3RecruitingUniversity College, London15002026-08-282026-11-04
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
Apalutamide (Erleada™) 60 mg or 240 mg tablets, Docetaxel - Metastatic Hormone-sensitive Prostate Cancer
Phase 3RecruitingAlianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD3202026-06-052026-06-17
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone - Metastatic Castration-resistant Prostate Cancer
Phase 3RecruitingAstraZeneca6702026-05-042026-10-19
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Androgen Therapy, Apalutamide, Docetaxel - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3RecruitingAlliance for Clinical Trials in Oncology12602025-12-012026-11-03
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer (Adenocarcinoma)
Phase 3RecruitingCanadian Cancer Trials Group8302025-05-282026-07-14
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
177Lu-PMSA-617, Standard of Care - Prostate Cancer Metastatic
Phase 3RecruitingUNICANCER5002024-09-122024-12-20
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
Apalutamide, Androgen Deprivation Therapy - Androgen Axis Suppression, Prostatectomy
Phase 3RecruitingM.D. Anderson Cancer Center1202024-09-102026-07-22
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
Apalutamide, Androgen-deprivation Therapy (ADT) - Metastatic Castrate-sensitive Prostate Cancer
Phase 3Active not recruitingJanssen Research & Development, LLC4202023-08-312026-09-25
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease - Prostate Cancer, Oligometastasis
Phase 2 / Phase 3Active not recruitingVA Office of Research and Development3782021-07-012026-11-05
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
Apalutamide, Bicalutamide, Biospecimen Collection - Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8
Phase 3Active not recruitingNRG Oncology27532021-01-212026-08-17
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Radiotherapy, LHRHa, Apalutamide - Prostatic Neoplasms
Phase 3Active not recruitingJanssen Pharmaceutica N.V., Belgium6912020-11-122026-11-03
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography - Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 3RecruitingECOG-ACRIN Cancer Research Group8042020-10-082026-11-13
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Apalutamide, Enzalutamide - Prostate Cancer
Phase 3TerminatedChinese University of Hong Kong742020-07-202026-10-27
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Prednisone, Apalutamide, Abiraterone Acetate - Prostate Cancer
Phase 3TerminatedDana-Farber Cancer Institute122020-04-202024-09-19
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
Apalutamide, Biospecimen Collection, Bone Scan - Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Phase 3Active not recruitingNRG Oncology5862020-04-162026-11-18
Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer
Radiation Therapy, Apalutamide, Luteinising Hormone Releasing Hormone analog agonist (LHRHa) - Prostate Cancer
Phase 3WithdrawnEuropean Organisation for Research and Treatment of Cancer - EORTC2020-03-102020-08-17
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
Apalutamide, Salvage radiotherapy (SRT), Luteinising Hormone Releasing Hormone agonist (LHRHa) - Prostate Cancer
Phase 3Active not recruitingUNICANCER4902020-01-092025-07-30
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Apalutamide, Androgen Deprivation Therapy (ADT), Placebo - Prostatic Neoplasms
Phase 3Active not recruitingJanssen Research & Development, LLC25172019-06-112026-11-03
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Enzalutamide Oral Capsule, Abiraterone Oral Tablet, Carboplatin - Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Phase 3RecruitingKarolinska Institutet7502019-02-012025-04-09
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Apalutamide, LHRH Analogue, Abiraterone Acetate - Prostate Cancer
Phase 3CompletedAlliance Foundation Trials, LLC.5032017-03-062026-11-09

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Prostatic Neoplasms (21)  ·  Neoplasm Metastasis (2)  ·  Adenocarcinoma (1)  ·  Genital Diseases, Male (1)  ·  Patient Preference (1)  ·  Prostatic Diseases (1)

Sponsors

Aragon Pharmaceuticals, Inc. (4)  ·  Janssen Research & Development, LLC (2)  ·  NRG Oncology (2)  ·  UNICANCER (2)  ·  Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD (1)  ·  Alliance Foundation Trials, LLC. (1)  ·  Alliance for Clinical Trials in Oncology (1)  ·  AstraZeneca (1)  ·  Canadian Cancer Trials Group (1)  ·  Chinese University of Hong Kong (1)  ·  Dana-Farber Cancer Institute (1)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Janssen Pharmaceutica N.V., Belgium (1)  ·  Karolinska Institutet (1)

Countries

United States (17)  ·  Canada (10)  ·  France (10)  ·  Germany (9)  ·  Spain (8)  ·  Australia (7)  ·  Brazil (7)  ·  Poland (7)  ·  United Kingdom (7)  ·  Belgium (6)  ·  Mexico (6)  ·  Russia (6)  ·  South Korea (6)  ·  Sweden (6)  ·  Czechia (5)

Top investigators

Abhishek Solanki, MD MS (1)  ·  Alexandra Sokolova (1)  ·  Ananya Choudhury, Professor (1)  ·  Anthony D'Amico, MD, PhD (1)  ·  Ashkan Mortezavi, MD, PhD (1)  ·  Chi Fai NG, MD (1)  ·  Evanthia Evanthia Galanis, MD (1)  ·  Gilles Crehange (1)  ·  Jan Oldenburg, Professor (1)  ·  Johan Lindberg, PhD (1)

Results publications

PMID 32878613, PMID 37951974, PMID 38421243, PMID 39163505, PMID 29420164, PMID 30213449, PMID 31150574, PMID 31578173, PMID 31980408, PMID 32586393, PMID 33914595, PMID 34039013, PMID 34600602, PMID 34797506, PMID 35213039, PMID 35317973, PMID 36082554, PMID 36209239, PMID 37071764, PMID 37708629, PMID 38261983, PMID 38421252, PMID 38940282, PMID 39058790, PMID 39164518, PMID 39405060, PMID 39889245, PMID 40132221, PMID 40263079, PMID 40645505, PMID 42223077, PMID 42616151, PMID 42728112

NIH funding

2023 (4), 2015 (2), U10CA180868 (2), 2014 (1), 2017 (1), 2018 (1), 2019 (1), 2025 (1), I01CX002277 (1), U10CA180820 (1)